Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HER3 shRNA
- Development stage
- Preclinical
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral, Intraperitoneal, Intrathecal
01
Overview
HER3 shRNA is a short hairpin RNA (shRNA) designed to silence the expression of the Human Epidermal Growth Factor Receptor 3 (HER3, also known as ERBB3). By utilizing the RNA interference (RNAi) pathway, the shRNA sequence—often delivered via viral vectors such as pLKO.1—targets HER3 mRNA for degradation, leading to a significant reduction in HER3 protein levels. In preclinical research, particularly in colorectal cancer models, HER3 knockdown has been shown to impede anchorage-independent growth and modulate the HER3-EREG signaling axis, which is associated with disease aggression and poor prognosis. This modality represents a targeted approach to inhibiting HER-family signaling in tumors that may be resistant to traditional EGFR-targeted therapies.
- Other names
- ERBB3 shRNAERBB-3 shRNAERBB 3 shRNAHER3 short hairpin RNAHER-3 short hairpin RNAHER 3 short hairpin RNAshRNA targeting HER3
02
Targets
ERBB3 (Erb-b2 receptor tyrosine kinase 3)Innate immune RNA sensors
Beyond the preview
Go deeper on HER3 shRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HER3 shRNA.